FDA panels to review bisphosphonate risks
Two U.S. Food and Drug Administration (FDA) advisory panels will meet this week to review the potential risks associated with long-term use of bisphosphonate medications such as Fosamax and to determine whether these drugs are safe and effective when used longer than three to five years, according to a story in the New York Times. Bisphosphonate drugs such as Fosamax and Zometa have been used for more than 15 years

